More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden ...

Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Cabaletta Bio, Inc.’s CABA share price has dipped by 15.52%, which has investors questioning if this is right time to buy.

Cabaletta has been evaluating the CAR-T, called resecabtagene autoleucel or rese-cel , across six so-called RESET studies ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...